Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | FGFR2 I288_E295delinsT |
Therapy | Debio 1347 |
Indication/Tumor Type | intrahepatic cholangiocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 I288_E295delinsT | intrahepatic cholangiocarcinoma | predicted - sensitive | Debio 1347 | Case Reports/Case Series | Actionable | In a clinical case study, Debio 1347 treatment in an intrahepatic cholangiocarcinoma patient harboring FGFR2 I288_E295delinsT led to a partial response with a 50% decrease in tumor burden, which was ongoing after 24 months (PMID: 33926920). | 33926920 |
PubMed Id | Reference Title | Details |
---|---|---|
(33926920) | FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. | Full reference... |